Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov.
Most participants first33,758 with no events in either group come last4,181 to 4,200 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| Restrictive Fluids vs Liberal Fluids: deaths from any cause | 172 of 768 169 of 773 | 0.5 points -3.6 to 4.7 | 1,541 | NCT03434028 Crystalloid Liberal or Vasopressors Early Resuscitation in Sepsis |
| 3M Skin and Nasal Antiseptic vs Bactroban Nasal: Surgical Site Infections Occurring Within 12 Months of Surgical Procedure | 0 of 776 5 of 763 | -0.7 points -1.5 to -0.0 | 1,539 | NCT01313182 Prevention of Surgical Site Infections: Effectiveness of Nasal Povidone-Iodine and Nasal Mupirocin |
| MK-4482 vs Placebo: deaths from any cause | 0 of 768 1 of 771 | -0.1 points -0.7 to 0.4 | 1,539 | NCT04939428 Study of MK-4482 for Prevention of Coronavirus Disease 2019 (COVID-19) in Adults (MK-4482-013) |
| LY2605541 vs Glargine: serious adverse events | 105 of 1,003 73 of 535 | -3.2 points -6.8 to 0.2 | 1,538 | NCT01435616 A Study in Patients With Type 2 Diabetes Mellitus |
| Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose: Hb Concentration of >12 g/dL at Any Time From Week 1 to Week 8 | 259 of 1,027 121 of 510 | 1.5 points -3.2 to 5.9 | 1,537 | NCT02940860 Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose for Treatment of Iron Deficiency Anemia in Non-Dialysis-Dependent Chronic Kidney Disease |
| Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose: Hb Concentration Increase of ≥2 g/dL at Any Time From Week 1 to Week 8 | 307 of 1,027 133 of 510 | 3.8 points -1.0 to 8.4 | 1,537 | NCT02940860 Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose for Treatment of Iron Deficiency Anemia in Non-Dialysis-Dependent Chronic Kidney Disease |
| Group 1: QIV-HD vs Group 2: QIV-SD: Number of Participants Reporting Unsolicited Adverse Events (AEs) | 190 of 772 172 of 761 | 2.0 points -2.2 to 6.3 | 1,533 | NCT04024228 Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Europeans Adults 60 Years of Age and Older |
| Group 1: QIV-HD vs Group 2: QIV-SD: Number of Participants Reporting Immediate Unsolicited Adverse Events (AEs) | 2 of 772 1 of 761 | 0.1 points -0.5 to 0.8 | 1,533 | NCT04024228 Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Europeans Adults 60 Years of Age and Older |
| Group 1 QIV-HD vs Group 2 QIV-SD: deaths from any cause | 2 of 772 0 of 761 | 0.3 points -0.3 to 0.9 | 1,533 | NCT04024228 Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Europeans Adults 60 Years of Age and Older |
| Group 1 QIV-HD vs Group 2 QIV-SD: serious adverse events | 17 of 772 21 of 761 | -0.6 points -2.2 to 1.0 | 1,533 | NCT04024228 Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Europeans Adults 60 Years of Age and Older |
| EEG Guided vs Usual Care: All-cause 30-day Mortality | 2 of 765 1 of 767 | 0.1 points -0.5 to 0.8 | 1,532 | NCT03330236 EEG - Guided Anesthetic Care and Postoperative Delirium |
| Fluid Restriction Group vs Standard-care: Number of Participants With One or More Serious Adverse Reactions (SARs) to IV Crystalloids in the ICU. | 31 of 755 32 of 776 | -0.0 points -2.0 to 2.0 | 1,531 | NCT03668236 The Conservative vs. Liberal Approach to Fluid Therapy of Septic Shock in Intensive Care Trial |
| Fluid Restriction Group vs Standard-care: serious adverse events | 221 of 755 238 of 776 | -1.4 points -6.0 to 3.2 | 1,531 | NCT03668236 The Conservative vs. Liberal Approach to Fluid Therapy of Septic Shock in Intensive Care Trial |
| Massive Transfusion Protocol (RBCs, Plasma, Platelets, Whole Blood) vs Early Cryoprecipitate + Massive Transfusion Protocol (RBCs, Plasma, Platelets, Whole Blood): Number of Participants With Mortality From Any Cause | 201 of 771 192 of 760 | 0.8 points -3.6 to 5.2 | 1,531 | NCT04704869 Early Use of Cryoprecipitate With Major Hemorrhage Protocol (MHP) Activation |
| Massive Transfusion Protocol (RBCs, Plasma, Platelets, Whole Blood) vs Early Cryoprecipitate + Massive Transfusion Protocol (RBCs, Plasma, Platelets, Whole Blood): deaths from any cause | 201 of 771 192 of 760 | 0.8 points -3.6 to 5.2 | 1,531 | NCT04704869 Early Use of Cryoprecipitate With Major Hemorrhage Protocol (MHP) Activation |
| PROMUS vs PROMUS Element: serious adverse events | 237 of 762 238 of 768 | 0.1 points -4.5 to 4.7 | 1,530 | NCT00823212 The PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery Lesions |
| Molnupiravir vs Placebo: Percentage of Participants With ≥1 Adverse Event | 94 of 763 105 of 765 | -1.4 points -4.8 to 2.0 | 1,528 | NCT04939428 Study of MK-4482 for Prevention of Coronavirus Disease 2019 (COVID-19) in Adults (MK-4482-013) |
| Molnupiravir vs Placebo: Percentage of Participants Discontinuing From Study Therapy Due to AE | 3 of 763 1 of 765 | 0.3 points -0.4 to 1.0 | 1,528 | NCT04939428 Study of MK-4482 for Prevention of Coronavirus Disease 2019 (COVID-19) in Adults (MK-4482-013) |
| MK-4482 vs Placebo: serious adverse events | 3 of 763 2 of 765 | 0.1 points -0.6 to 0.9 | 1,528 | NCT04939428 Study of MK-4482 for Prevention of Coronavirus Disease 2019 (COVID-19) in Adults (MK-4482-013) |
| Molnupiravir vs Placebo: Percentage of Participants (Regardless of SARS-CoV-2 in Baseline NP Swabs) Who Developed COVID-19 (Laboratory-Confirmed SARS-CoV-2 Infection With Symptoms) Through Day 14 | 78 of 763 103 of 764 | -3.3 points -6.5 to -0.0 | 1,527 | NCT04939428 Study of MK-4482 for Prevention of Coronavirus Disease 2019 (COVID-19) in Adults (MK-4482-013) |
Code
curl "https://conductscience.org/api/comparisons/v1?page=210"
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=210
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT03434028-deaths",
"title": "Restrictive Fluids vs Liberal Fluids: deaths from any cause",
"summary": "172 of 768 against 169 of 773; risk difference 0.5 points, 95% interval -3.6 to 4.7; NCT03434028, Crystalloid Liberal or Vasopressors Early Resuscitation in Sepsis",
"record": "/library/comparisons/NCT03434028-deaths",
"nct_id": "NCT03434028",
"kind": "deaths",
"participants": 1541,
"risk_difference": {
"value": 0.005329614057783538,
"lower": -0.0361128315907545,
"upper": 0.04677035695592194
},
"group_1": "172 of 768",
"group_2": "169 of 773",
"difference": "0.5 points",
"interval": "-3.6 to 4.7",
"trial_title": "Crystalloid Liberal or Vasopressors Early Resuscitation in Sepsis"
},
{
"id": "NCT01313182-152c99a6",
"title": "3M Skin and Nasal Antiseptic vs Bactroban Nasal: Surgical Site Infections Occurring Within 12 Months of Surgical Procedure",
"summary": "0 of 776 against 5 of 763; risk difference -0.7 points, 95% interval -1.5 to -0.0; NCT01313182, Prevention of Surgical Site Infections: Effectiveness of Nasal Povidone-Iodine and Nasal Mupirocin",
"record": "/library/comparisons/NCT01313182-152c99a6",
"nct_id": "NCT01313182",
"kind": "outcome",
"participants": 1539,
"risk_difference": {
"value": -0.00655307994757536,
"lower": -0.015247724626428953,
"upper": -0.00036165105609137476
},
"group_1": "0 of 776",
"group_2": "5 of 763",
"difference": "-0.7 points",
"interval": "-1.5 to -0.0",
"trial_title": "Prevention of Surgical Site Infections: Effectiveness of Nasal Povidone-Iodine and Nasal Mupirocin"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "No license stated"
}
],
"next": "/api/comparisons/v1?page=211",
"request_id": "OQpgxDps276MlaR5"
}Ask about these results. The first 10 go in the prompt.
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
Opens sequences.conductscience.org
Open Targets
One drug with its targets, the diseases it is studied for, and the trials that name it, with their comparisons, papers and cognitive tests.
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant